Revvity at Baird Global Healthcare Conference: Steady Growth Amid Challenges

Revvity Inc. reported Q2 results slightly exceeding expectations, driven by robust high-teens growth in its software segment and consistent low single-digit growth in consumables. However, the company faces significant headwinds, including a 25% decline in its China diagnostics business due to new DRG policy changes expected to persist into next year, and ongoing mid-to-high single-digit declines in instrument sales. Despite these challenges, Revvity remains confident in its long-term trajectory, targeting a 28% operating margin by 2026, pursuing strategic initiatives like the Genomics England contract, and actively repurchasing shares, signaling management's belief in future prospects.

Analysis

Revvity Inc. (RVTY) presented a mixed operational overview at the Baird Global Healthcare Conference, with Q2 results slightly surpassing expectations on both revenue and profit. The company's software business, which constitutes 9% of total revenue, is a significant bright spot, demonstrating robust growth in the high teens that outpaces its 9-11% long-term plan and is set for further expansion with a key new product launch for large molecule workflows. This strength, along with stable low single-digit growth in consumables for the fifth consecutive quarter, is contrasted by significant headwinds. The diagnostics segment, representing half of company revenue, faces a material challenge in China, where new DRG policies are expected to cause a 25% revenue decline in that specific business line for the second half of the year. Furthermore, instrument sales continue a multi-year decline, down mid-to-high single digits due to market uncertainty. Despite these pressures and a 50-basis-point margin impact from tariffs, management is targeting a 28% operating margin baseline by 2026 and has signaled strong confidence through an aggressive share repurchase program, having bought back nearly 9% of the company's stock over the past twelve months.

Key Decisions for Investors

• Investors should closely track the performance of the high-growth software segment, as its continued outperformance and the successful launch of its new large molecule product are critical to offsetting weakness in other areas.
• The 25% projected decline in the China diagnostics business is a major near-term risk, and positions should be managed with an eye on any signs of stabilization or further policy impact leading up to the anniversary of the headwind in mid-2026.
• The aggressive share repurchase program signals strong management conviction in the long-term equity value, suggesting that current headwinds may present an opportunity for investors who believe the market challenges are temporary.
• Monitor progress on the Genomics England newborn sequencing contract and the expansion of diagnostic approvals in the U.S., as these are key potential catalysts for revenue growth and improved market sentiment.